The Accorson FC-BP220 is a premium wrist blood pressure monitor designed to simplify health tracking at home. Featuring a large, backlit LCD screen for clear visibility, it provides immediate readings of Systolic, Diastolic, and Pulse. Key features include Voice Broadcast for auditory feedback, WHO Blood Pressure Classification for instant health assessment, and Arrhythmia Detection. It also supports Two-User Memory storage and calculates the Average of the Last 3 Readings (AVG), making it a reliable and accessible tool for comprehensive family health management. The product is licensed by the Ministry of Health of Vietnam, ensuring its credibility and quality.
The Accorson FC-BP220 is engineered for precision and user comfort. Its large LCD screen features a backlight, ensuring that readings—Systolic, Diastolic, and Pulse—are clearly visible even in low light conditions. The integrated Voice Broadcast function reads out the measurement results, addressing the needs of users with impaired vision.
For instant self-assessment, the monitor uses the WHO Blood Pressure Classification indicator, presenting a quick color-coded status of the measurement result according to global health standards. To facilitate long-term health tracking for a family, the device offers Two-User Memory Storage, allowing two individuals to independently save their history. It also includes an essential Arrhythmia Detection feature, which alerts the user to any irregularities in their heartbeat rhythm detected during the measurement. To provide a stable and accurate health benchmark, the FC-BP220 can instantly calculate the Average of Last 3 Readings (AVG), which smooths out daily fluctuations for a more reliable assessment.
Crucially, this device has received the official Product License from the Ministry of Health (Publication No.: 250002513/PCBB-HN, dated 11/08/2025), guaranteeing compliance with national quality and safety standards.
The product is licensed by the Ministry of Health with Publication Number: 250002513/PCBB-HN dated 11/08/2025.